EMMPRIN and survivin: prognostic factors in cisplatin-treated patients with bladder cancer

被引：0
|
作者：
机构：
来源：
Nature Clinical Practice Oncology | 2007年 / 4卷 / 12期
关键词：
D O I：
10.1038/ncponc0938
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：676 / 676
相关论文
共 50 条
  • [1] Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer
    Als, Anne B.
    Dyrskjot, Lars
    von der Maase, Hans
    Koed, Karen
    Mansilla, Francisco
    Toldbod, Helle E.
    Jensen, Jens L.
    Ulhoi, Benedicte P.
    Sengelov, Lisa
    Jensen, Klaus M. E.
    Orntoft, Torben F.
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4407 - 4414
  • [2] Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients
    Surowiak, P
    Materna, V
    Kaplenko, I
    Spaczynski, M
    Dietel, M
    Lage, H
    Zabel, M
    VIRCHOWS ARCHIV, 2005, 447 (03) : 626 - 633
  • [3] Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients
    Paweł Surowiak
    Verena Materna
    Irina Kaplenko
    Marek Spaczyński
    Manfred Dietel
    Hermann Lage
    Maciej Zabel
    Virchows Archiv, 2005, 447 : 626 - 633
  • [4] Trends in ototoxicity monitoring among cisplatin-treated patients with cancer
    Lee, David S.
    Travis, Emma Y.
    Wong, Susan K.
    Munyemana, Marie-Ange
    Mueller, Lauren
    Rowling, Cathryn Collopy
    Rich, Jason T.
    Pipkorn, Patrik
    Puram, Sidharth V.
    Jackson, Ryan S.
    Adkins, Douglas R.
    Oppelt, Peter
    Thorstad, Wade L.
    Wick, Cameron C.
    Zevallos, Jose P.
    Mcclannahan, Kate
    Mazul, Angela L.
    JOURNAL OF CANCER SURVIVORSHIP, 2024,
  • [5] Prognostic value of Survivin in patients with bladder cancer
    Karam, Jose
    Shariat, Shahrokh
    Karakiewicz, Pierre
    Fradet, Yves
    Capitano, Umberto
    Ashfaq, Raheela
    Montorsi, Francesco
    Bastian, Patrick
    Nielsen, Matthew
    Muller, Stefan
    Rigaud, Jerome
    Heukamp, Lukas
    Netto, George
    Lerner, Seth
    Sagalowsky, Arthur
    Lotan, Yair
    CANCER RESEARCH, 2009, 69
  • [6] Chemosensitizer effect of cisplatin-treated bladder cancer cells by phenazine-5,10-dioxides
    Hernandez, Paola
    Alem, Diego
    Nieves, Marcos
    Cerecetto, Hugo
    Gonzalez, Mercedes
    Martinez-Lopez, Wilner
    Laura Lavaggi, Maria
    ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2019, 69 : 9 - 15
  • [7] Investigation of differentially expressed gene profile for cisplatin-treated lung cancer patients
    Gu, Songtao
    Wu, Qi
    Li, Yuechuan
    Jia, Wei
    Zhang, Dongrui
    Jiao, Lina
    Zhang, Yating
    ANTI-CANCER DRUGS, 2021, 32 (08) : 875 - 881
  • [8] Prognostic factors in patients with advanced gastric cancer treated with cisplatin plus fluoropyrimidine
    Fukuda, Naoki
    Ohhara, Yoshihito
    Hirata, Yuya
    Yokoyama, Fumiaki
    Ishibashi, Yoko
    Sugai, Nozomu
    Seki, Hideyuki
    Fujita, Jun
    Suzuki, Junichi
    ANNALS OF ONCOLOGY, 2015, 26 : 133 - 133
  • [9] Medroxyprogesterone Acetate for Refractory Emesis in Cisplatin-Treated Patients
    Hata, Akito
    Katakami, Nobuyuki
    Fujita, Shiro
    Horai, Aya
    Takatori, Kento
    Ose, Takayuki
    Kitajima, Naoto
    JOURNAL OF PALLIATIVE MEDICINE, 2012, 15 (10) : 1158 - 1160
  • [10] AN ANALYSIS OF FACTORS RESPONSIBLE FOR RESORPTION OF EMBRYOS IN CISPLATIN-TREATED RATS
    BAJT, ML
    AGGARWAL, SK
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 1985, 80 (01) : 97 - 107
12345